Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Greater Biosimilar Uptake Found in Medicare Advantage Than Traditional Medicare

January 21st 2024

By Cameron Santoro

Article

Biosimilar uptake was greater in Medicare Advantage plans when compared with traditional Medicare plans.

Postapproval Pharmacovigilance Review Confirms Comparable Safety Between Sandoz Biosimilars, Originators

January 20th 2024

By Deana Ferreri, PhD

Article

Authors of a review of available postapproval pharmacovigilance data assessing 8 Sandoz biosimilars concluded that these biosimilars “can be used as safely as their respective reference biologics.”

The Top 5 Biosimilar Articles for the Week of January 15

January 19th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 15, 2024.

IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition

January 18th 2024

By Skylar Jeremias

Article

The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.

SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy

January 17th 2024

By Skylar Jeremias

Article

As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.

Study Highlights Role of Health Plan Type in Biosimilar Adoption

January 16th 2024

By Skylar Jeremias

Article

A study examining biosimilar uptake patterns within different health insurance plans found that low-flexibility plans, such as health maintenance organizations and exclusive provider organizations, were more likely to initiate biosimilar therapies than more flexible plans.

Rituximab Biosimilars Effective in Treating Immune Thrombocytopenia

January 15th 2024

By Cameron Santoro

Article

A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia.

FDA Approves First Biosimilar for Neulasta Onpro

January 15th 2024

By Skylar Jeremias

Article

The FDA has approved Coherus Biosciences’ on-body injector version of Udenyca (pegfilgrastim-cbqv), making it the first biosimilar to reference Neulasta Onpro, the pegfilgrastim product that holds the majority of the pegfilgrastim market share.

Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape

January 14th 2024

By Skylar Jeremias

Article

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.

Proposed Bevacizumab Biosimilar Demonstrates Clinical Equivalence to Avastin in NSCLC

January 13th 2024

By Deana Ferreri, PhD

Article

The proposed bevacizumab biosimilar BAT1706 (Bio-Thera Solutions) demonstrated equivalence to the reference product (Avastin) in a phase 3 comparative efficacy trial in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).